A new class of anti Alzheimer's molecule
.
Alzheimer's Donation
Donate Online Now
.
A 2006 study by MetLife found that adults over age 55 fear Alzheimer's disease more than cancer, and with good reason. Alzheimer's creeps up on patients and their families, robbing more than half of all Americans over age 85 of their memory and ability to care for themselves. But what is perhaps most frightening is that available treatments for the disease are by and large ineffective.
Research from Georgetown University several years ago suggested that a new class of anti Alzheimer's molecule, spirostenols, might undo some of the characteristic pathophysiology of Alzheimer affected brains. Further testing showed that one such molecule, Caprospinol, actually reversed the course of an Alzheimer like condition induced in rats. Today, Samaritan Pharmaceuticals (Las Vegas, NV), is gearing up for human clinical studies with this compound, also known as SP-233.
Buildup of beta-amyloid plaque in the brain has been recognized as a hallmark sign of Alzheimer's for close to a century. Significant research points to this buildup as a causative factor in the development and progression of the disease. Until recently this hypothesis could not be tested definitively because of a lack of treatments that eliminate beta-amyloid plaques.
Samaritan Pharmaceutical scientists, working with leading researchers from Georgetown and McGill Universities, have demonstrated in a rat animal model, used to test new innovative drugs for Alzheimer's disease, that Caprospinol clears amyloid plaque from the brain and restored memory. More impressively, treated rats perform as well or better in standardized behavioral tests than healthy control animals. In addition to eliminating plaque, Caprospinol appears to reverse the damage to memory and cognition that amyloid plaque causes.
Dr. Vassilios Papadopoulos, of McGill University Health Center, an adviser to Samaritan, and the discoverer of anti-Alzheimer's spirostenols recently published a paper reviewing current development-stage approaches to treating Alzheimer's disease (Recent Patents on CNS Drug Discovery, 2007, 2, 113-123). In this article, he identified amyloid plaque as a key target for therapy. The paper also summarized the research on acetylcholinesterase inhibitors as well as beta-amyloid aggregation inhibitors, of which Caprospinol is an example.
The rat studies were conducted by treating rats with a method of inducing an Alzheimer's like condition in test animals within four weeks. Rats treated in this fashion gradually lose cognitive skills, as well exhibiting a host of pathophysiologic brain changes indicative of Alzheimer's. Then treatment of sick rats with Caprospinol brought about significant positive changes in brain pathology. Neuritic plaques, neurofibrillary tangles, astrogliosis, microgliosis, neuronal death, and tissue shrinking were all either reversed or markedly improved. http://www.medicalnewstoday.com
Scientists develop prebiotic, low-fat sausages
Inulin, the prebiotic fibre associated with improved gut and bone health, can be used as a fat replacer in sausages to cut energy by over 20 per cent without affecting the flavour profile, suggests new research.
posted YVN
.
Alzheimer's Donation
Donate Online Now
.
A 2006 study by MetLife found that adults over age 55 fear Alzheimer's disease more than cancer, and with good reason. Alzheimer's creeps up on patients and their families, robbing more than half of all Americans over age 85 of their memory and ability to care for themselves. But what is perhaps most frightening is that available treatments for the disease are by and large ineffective.
Research from Georgetown University several years ago suggested that a new class of anti Alzheimer's molecule, spirostenols, might undo some of the characteristic pathophysiology of Alzheimer affected brains. Further testing showed that one such molecule, Caprospinol, actually reversed the course of an Alzheimer like condition induced in rats. Today, Samaritan Pharmaceuticals (Las Vegas, NV), is gearing up for human clinical studies with this compound, also known as SP-233.
Buildup of beta-amyloid plaque in the brain has been recognized as a hallmark sign of Alzheimer's for close to a century. Significant research points to this buildup as a causative factor in the development and progression of the disease. Until recently this hypothesis could not be tested definitively because of a lack of treatments that eliminate beta-amyloid plaques.
Samaritan Pharmaceutical scientists, working with leading researchers from Georgetown and McGill Universities, have demonstrated in a rat animal model, used to test new innovative drugs for Alzheimer's disease, that Caprospinol clears amyloid plaque from the brain and restored memory. More impressively, treated rats perform as well or better in standardized behavioral tests than healthy control animals. In addition to eliminating plaque, Caprospinol appears to reverse the damage to memory and cognition that amyloid plaque causes.
Dr. Vassilios Papadopoulos, of McGill University Health Center, an adviser to Samaritan, and the discoverer of anti-Alzheimer's spirostenols recently published a paper reviewing current development-stage approaches to treating Alzheimer's disease (Recent Patents on CNS Drug Discovery, 2007, 2, 113-123). In this article, he identified amyloid plaque as a key target for therapy. The paper also summarized the research on acetylcholinesterase inhibitors as well as beta-amyloid aggregation inhibitors, of which Caprospinol is an example.
The rat studies were conducted by treating rats with a method of inducing an Alzheimer's like condition in test animals within four weeks. Rats treated in this fashion gradually lose cognitive skills, as well exhibiting a host of pathophysiologic brain changes indicative of Alzheimer's. Then treatment of sick rats with Caprospinol brought about significant positive changes in brain pathology. Neuritic plaques, neurofibrillary tangles, astrogliosis, microgliosis, neuronal death, and tissue shrinking were all either reversed or markedly improved. http://www.medicalnewstoday.com
Scientists develop prebiotic, low-fat sausages
Inulin, the prebiotic fibre associated with improved gut and bone health, can be used as a fat replacer in sausages to cut energy by over 20 per cent without affecting the flavour profile, suggests new research.
posted by Valery Yermalitsky at
6:15 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home